Trial results for a study comparing pharmacotherapy regimens for Type 2 Diabetes Mellitus and Cardiovascular Diseases, including Empagliflozin, were posted on ClinicalTrials.gov on 2025-11-21. The study enrolled 241,981 participants and detailed the incidence of 3-point Major Adverse Cardiovascular Events (MACE) across different glucose-lowering medication classes.
Background
The study, titled "Comparison of Type 2 Diabetes Pharmacotherapy Regimens," aimed to evaluate various glucose-lowering medications, including SGLT2 inhibitors like Empagliflozin, for their effects on heart health and other patient outcomes in individuals with Type 2 Diabetes Mellitus and Cardiovascular Diseases. The research sought to inform clinicians on medication selection, timing of initiation, and potential differences in benefits across diverse patient populations based on factors such as age, sex, race/ethnicity, and baseline health status.
Trial design
The study (NCT05073692), titled "Comparison of Type 2 Diabetes Pharmacotherapy Regimens," was a completed study that enrolled 241,981 participants. It investigated pharmacotherapy regimens for individuals with Type 2 Diabetes Mellitus and Cardiovascular Diseases. The interventions included various classes of glucose-lowering medications: sulfonylureas (SU), dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA), as well as a group initiating either an SGLT2i or GLP-1RA.
Key results
The study reported the incidence of 3-point Major Adverse Cardiovascular Events (MACE) across different medication initiation groups:
- Among SU Initiators, the incidence of 3-point MACE was observed in 11,348 Participants.
- Among DPP4 Initiators, the incidence of 3-point MACE was observed in 393 Participants.
- Among SGLT2i Initiators (which includes Empagliflozin), the incidence of 3-point MACE was observed in 424 Participants.
- Among GLP-1RA Initiators, the incidence of 3-point MACE was observed in 296 Participants.
What this means
The posted trial results provide important data on the incidence of 3-point Major Adverse Cardiovascular Events (MACE) among patients initiating different classes of glucose-lowering medications for Type 2 Diabetes Mellitus and Cardiovascular Diseases. This information contributes to a broader understanding of cardiovascular outcomes associated with various pharmacotherapy regimens, including SGLT2 inhibitors such as Empagliflozin, and can help inform future clinical decision-making regarding treatment strategies for these patient populations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05073692, titled "Comparison of Type 2 Diabetes Pharmacotherapy Regimens," were posted on 2025-11-21 on clinicaltrials.gov.